Brainsway (BWAY) Expected to Announce Quarterly Earnings on Tuesday

Brainsway (NASDAQ:BWAY) is expected to be posting its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to announce earnings of $0.12 per share and revenue of $17.81 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:00 AM ET.

Brainsway (NASDAQ:BWAY) last released its earnings results on Wednesday, August 12th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. The company had revenue of $17.11 million for the quarter, compared to analysts’ expectations of $16.54 million. On average, analysts expect Brainsway to post $0.33 EPS for the current fiscal year and $0.57 EPS for the next fiscal year.

Brainsway Trading Up 0.9%

NASDAQ BWAY traded up $0.10 on Tuesday, reaching $11.19. 20,941 shares of the stock were exchanged, compared to its average volume of 147,005. Brainsway has a one year low of $7.14 and a one year high of $17.40. The firm has a market capitalization of $450.20 million, a PE ratio of 25.42 and a beta of 1.29. The company’s 50-day simple moving average is $12.88 and its two-hundred day simple moving average is $13.93.

Analyst Ratings Changes

BWAY has been the subject of a number of analyst reports. BTIG Research reissued a “buy” rating and issued a $20.00 price objective on shares of Brainsway in a research note on Thursday, September 10th. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. HC Wainwright restated a “buy” rating on shares of Brainsway in a research note on Friday. LADENBURG THALM/SH SH upped their target price on shares of Brainsway from $18.00 to $18.80 and gave the stock a “buy” rating in a report on Thursday, August 13th. Finally, Weiss Ratings downgraded shares of Brainsway from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.20.

Brainsway Company Profile

BrainsWay Ltd. (NASDAQ: BWAY) is a medical technology company that develops and commercializes noninvasive therapies for brain disorders. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses a helmet-like device to deliver magnetic stimulation to targeted areas of the brain.

The company’s Deep TMS systems are used in the treatment of major depressive disorder and obsessive-compulsive disorder, and have also received regulatory clearances for certain additional indications, including smoking cessation.